Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CLDX
CELLDEX THERAPEUTICS, INC.
NASDAQ
$39.12
▼ DOWN 3.31% (-1.34)

KEY STATISTICS

Market Cap$2.60 B
52w High$45.14
52w Low$21.77
Dividend Yield—
Frequency—
P/E-9.18
Volume424.94K
Shares Out.66.54M

COMPANY

LEADERSHIP

Anthony S. Marucci
CHIEF EXECUTIVE
Anthony S. Marucci

COMPENSATION 2026

Salary$785,804
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$19,015
Total$5,366,709

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 15, 1986
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
198

PRICE TARGET

Target High$100.00
Target Low$40.00
Target Median$60.50
Target Consensus$62.63

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$725.75K
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2019-02-11Reverse1:15
2008-03-10Reverse1:12

PRICE

$39.12 ▼ DOWN 3.31% (−$1.34)
OVERLAYS
$39.00$39.50$40.00$40.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM39.12

About Celldex Therapeutics, Inc.

https://www.celldex.com ↗

Celldex Therapeutics develops monoclonal and bispecific antibody therapeutics for cancer and inflammatory diseases, with programs like CDX-0159, CDX-1140, and CDX-527, collaborating with universities and biotech partners.

INDUSTRY

Biotechnology

A PRODUCT CELLDEX THERAPEUTICS, INC. IS KNOWN FOR

Barzolvolimab
Barzolvolimab

Barzolvolimab is Celldex's lead monoclonal antibody targeting KIT, currently in late-stage trials for chronic urticaria and inflammatory/allergic diseases.

COMPETITORS

COMPETITOR
NVS COMPARE
REGN COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Grant$1.37M $0 ▼$15K ▲$15K
Service$57K $0 ▼— $7K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
138
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 2.5M
XBI
0.73% · 2.2M
XSU.TO
0.10% · 2.0M
SCHA
0.07% · 373.2K
DFAS
0.05% · 202.1K
TMSL
0.21% · 158.0K
SBIO
1.57% · 96.6K
LABU
0.50% · 78.3K
XRSG.L
0.10% · 70.0K
PRFZ
0.07% · 51.1K
FYC
0.14% · 50.1K
FFSM
0.13% · 42.6K
RSSL
0.10% · 37.3K
SURI
1.30% · 28.8K
BBSC
0.10% · 18.5K
BBC
0.77% · 10.0K
WDNA.L
0.92% · 7.6K
RTWO.L
0.14% · 7.6K
GSSC
0.03% · 7.5K
ACSG
0.38% · 4.9K
TILT
0.01% · 4.9K
RFLR
0.15% · 3.7K
URTY
0.04% · 3.2K
VETS
0.11% · 994
AVUS
0.00% · 636
USFMDN.MX
0.01% · 341

INSTITUTIONAL OWNERSHIP

SHARES OWNED
87.76%
HOLDERS
309
TOP 12 OF 309 · RANKED BY POSITION SIZE
Wellington Management Group Llp
9.5M sh · $355.12M
Blackrock, Inc.
7.0M sh · $260.56M
Kynam Capital Management, LP
6.1M sh · $157.83M
Fmr LLC
5.0M sh · $128.37M
Blackrock Inc.
4.7M sh · $173.61M
Price T Rowe Associates Inc /Md/
4.7M sh · $174.34M
Vanguard Group Inc
4.0M sh · $109.38M
State Street Corp
3.9M sh · $145.13M
Point72 Asset Management, L.P.
3.9M sh · $100.74M
Bellevue Group AG
3.6M sh · $98.26M
Commodore Capital LP
3.0M sh · $78.34M
Deep Track Capital, LP
2.9M sh · $109.37M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Cohen Cheryl
Purchase · 26.0K shares
2026-06-25
★
OFFICER: SVP AND CFO
Martin Samuel Bates
Purchase · 93.0K shares
2026-06-25
★
DIRECTOR
Brownlie Keith L
Purchase · 26.0K shares
2026-06-25
★
OFFICER: SVP OF CORP AFFAIRS & ADMIN.
Cavanaugh Sarah
Purchase · 95.0K shares
2026-06-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 4
NEUTRAL 1
10 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT Barclays OVERWEIGHT Wells Fargo OVERWEIGHT Canaccord Genuity BUY Cantor Fitzgerald OVERWEIGHT Guggenheim BUY HC Wainwright & Co. BUY UBS BUY

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
ABCL$11.35COMPARE
QURE$48.72COMPARE
IMNM$27.57COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
HRMY$39.21COMPARE